Life Healthcare Group Holdings (JSE:LHC) Research & Development: R0 Mil (TTM As of Mar. 2026)


JSE:LHC Life Healthcare Group Holdings Ltd JSE:LHC
56 GF Score
Price R10.43
GF Value R15.61
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Life Healthcare Group Holdings Research & Development?

Life Healthcare Group Holdings JSE:LHC +1.16% 56 Research & Development is R0 Mil as of Mar. 2026. GuruFocus rates JSE:LHC with a GF Score™ of 56/100 and a GF Value™ of R15.61 (Possible Value Trap). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Life Healthcare Group Holdings's Research & Development for the six months ended in Mar. 2026 was R0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was R0 Mil.

Life Healthcare Group Holdings  (JSE:LHC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Life Healthcare Group Holdings Research & Development Related Terms

Life Healthcare Group Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Life Healthcare Group Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Life Healthcare Group Holdings Research & Development Chart

Life Healthcare Group Holdings Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Life Healthcare Group Holdings Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
JSE:LHC
56GF Score
Life Healthcare Group Holdings Ltd JSE:LHC
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Life Healthcare Group Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was R0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of R0 Mil mean?
Life Healthcare Group Holdings (JSE:LHC) has a Research & Development of R0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Life Healthcare Group Holdings and its competitors.
Is Life Healthcare Group Holdings' Research & Development too high?
Life Healthcare Group Holdings' current Research & Development is R0 Mil. Overall, Life Healthcare Group Holdings has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Life Healthcare Group Holdings' Research & Development compare to HCA and THC?
Life Healthcare Group Holdings' Research & Development of R0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Life Healthcare Group Holdings and its competitors. Life Healthcare Group Holdings's current Research & Development is R0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Life Healthcare Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, Life Healthcare Group Holdings (JSE:LHC) is currently considered Possible Value Trap. The stock's GF Value™ is R15.61, compared to a current price of R10.43 — trading 33.2% below its estimated fair value. The current Research & Development is R0 Mil. Life Healthcare Group Holdings' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Life Healthcare Group Holdings (JSE:LHC), the current Research & Development is R0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Life Healthcare Group Holdings (JSE:LHC) Overvalued in 2026?

Based on GuruFocus' analysis, Life Healthcare Group Holdings stock appears to be undervalued. The current stock price of R10.43 is trading 33.2% below its estimated GF Value™ of R15.61. GuruFocus considers Life Healthcare Group Holdings to be Possible Value Trap.

Key valuation signals for JSE:LHC:

  • Research & Development: R0 Mil
  • GF Value™: R15.61 vs. price of R10.43 (33.2% below fair value)
  • GF Score™: 56/100 with 3 warning signs

No single metric tells the full story. See the JSE:LHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Life Healthcare Group Holdings Business Description

Address 203 Oxford Road, Oxford Parks, Corner Eastwood and Oxford Roads, Dunkeld, Johannesburg, GT, ZAF, 2196
Life Healthcare Group Holdings Ltd is a private healthcare provider in southern Africa, prominently serving the medically insured market. The company is in the business of providing hospital and complementary services (which include mental healthcare, acute rehabilitation, renal dialysis, oncology and diagnostics) and healthcare services. It operates via three segments: Hospitals segment (acute hospitals), the Complementary Services segment (mental health, acute rehabilitation, renal dialysis, oncology and diagnostics) and the Healthcare Services segment (Life Nkanyisa and Life Health Solutions). The majority of revenue is derived from the hospitals segment. Geographically, the company generates the maximum revenue from Southern Africa.
56GF Score

Get the complete analysis for JSE:LHC

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R10.43
Price
R15.61
GF Value